About Kinnate Biopharma
Kinnate Biopharma is a company based in San Diego (United States) founded in 2018 by Eric Murphy and Steve Kaldor was acquired by XOMA Corporation in February 2024.. Kinnate Biopharma has raised $172.5 million across 2 funding rounds from investors including Fidelity Investments, Citadel and Orbimed. The company has 30 employees as of December 31, 2020. Kinnate Biopharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Diego, United States
- Employees 30 as on 31 Dec, 2020
- Founders Eric Murphy, Steve Kaldor
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Kinnate Biopharma Inc.
-
Annual Revenue
-
Net Profit
$-112.65 M3as on Dec 31, 2023
-
EBITDA
$-121.18 M-2as on Dec 31, 2023
-
Total Equity Funding
$172.5 M (USD)
in 2 rounds
-
Latest Funding Round
$98 M (USD), Series C
Jul 21, 2020
-
Investors
Fidelity Investments
& 14 more
-
Employee Count
30
as on Dec 31, 2020
-
Acquired by
XOMA Corporation
(Feb 16, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Kinnate Biopharma
Kinnate Biopharma has successfully raised a total of $172.5M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $98 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series C — $98.0M
-
First Round
First Round
(12 Dec 2019)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2020 | Amount | Series C - Kinnate Biopharma | Valuation | RA Capital Management | |
| Dec, 2019 | Amount | Series B - Kinnate Biopharma | Valuation | Orbimed , Nextech Invest |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kinnate Biopharma
Kinnate Biopharma has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Citadel and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kinnate Biopharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Kinnate Biopharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kinnate Biopharma Comparisons
Competitors of Kinnate Biopharma
Kinnate Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Kinnate Biopharma
Frequently Asked Questions about Kinnate Biopharma
When was Kinnate Biopharma founded?
Kinnate Biopharma was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is Kinnate Biopharma located?
Kinnate Biopharma is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Kinnate Biopharma?
Steve Kaldor is the current CEO of Kinnate Biopharma. They have also founded this company.
Is Kinnate Biopharma a funded company?
Kinnate Biopharma is a funded company, having raised a total of $172.5M across 2 funding rounds to date. The company's 1st funding round was a Series B of $74.5M, raised on Dec 12, 2019.
How many employees does Kinnate Biopharma have?
As of Dec 31, 2020, the latest employee count at Kinnate Biopharma is 30.
What does Kinnate Biopharma do?
Kinnate Biopharma was founded in 2018 and is headquartered in San Diego, United States. Small molecule therapeutics are developed for cancer treatment within the biopharmaceutical sector. Operations center on three programs: precision oncology targeting DNA damage repair mechanisms, inhibitors addressing gene rearrangements with known resistance mutations, and inhibitors for a pathway validated clinically across various cancers.
Who are the top competitors of Kinnate Biopharma?
Kinnate Biopharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Who are Kinnate Biopharma's investors?
Kinnate Biopharma has 15 investors. Key investors include Fidelity Investments, Citadel, Orbimed, Janus Henderson Investors, and RA Capital.